About

Helmsley is the largest private philanthropy focused on Crohn’s disease, a complex, chronic inflammatory bowel disease that impacts more than 2 million people around the world. We are committed to addressing the unmet needs of people living with the disease, investing in research and technologies that will improve care and treatment for patients, and finding a cure.

Collaboration is essential to achieving our goals. We partner with organizations to support new research and ideas, and have built a network of researchers, institutions, and organizations working to find a cure for Crohn’s disease. We encourage our grantees to tap into this network, work together, and share ideas.

Our work focuses on funding in five key and interrelated areas: prevention, disease management, therapeutics, diagnostics, and disease biology.

Prevention

The causes of Crohn’s disease involve a complex interplay among a patient’s genetic makeup, their immune system, and environmental factors, but the details are poorly understood. We support research to uncover further its root causes and identify how the disease develops.

The number of people living with Crohn’s disease is on the rise globally, particularly in newly industrialized countries across Africa, Asia, and South America, where previously there were few cases. Studying the factors driving this increase could provide important new insights into its causes and identify how the disease develops.

Diet plays a major role in Crohn’s disease. We fund research to better understand the effects of different foods on intestinal health, and on gut microbes, which are known to play a role in the disease, and to guide dietary choices that will benefit patients.

Diagnostics

Accessible, accurate, non-invasive, and cost-effective diagnostics will enable more precise treatment decisions as well as timely monitoring for people with Crohn’s disease – which can inform further fine-tuning of therapeutic plans. Helmsley funding supports the development of biomarkers, indices and standards, patient reported outcomes, imaging modalities, and other novel technologies and devices, to improve personalized care and lead to better outcomes.

Therapeutics

About half of Crohn’s disease patients do not respond to available therapies, so the need for new and more effective treatments is critical. Helmsley invests in research to understand the mechanisms underlying the disease and to identify and test novel therapies to accelerate the development of new treatments.

As the underlying mechanisms driving the disease are thought to vary among patients, individualizing patient treatment is a priority in Crohn’s disease. Investigating new therapeutics and optimizing existing treatment regimens will allow for improved patient outcomes.

Disease Management

Once a person is diagnosed with Crohn’s disease, they are met with a lifelong challenge that requires daily action and care to help with managing their disease. Patients deserve easily accessible, high-quality care built on informed, collaborative decision-making with their providers.

Patients and their caregivers need better tools and resources which are accessible for all regardless of geography. This includes leveraging technology to improve quality of life, monitoring symptoms to detect and predict flares, and improving access to mental healthcare resources, which can help mitigate the stress that is often caused by dealing with a chronic disease like Crohn’s.

Disease Biology

Research into how environmental factors imprint on biological processes like gene expression may help reveal underlying causes of Crohn’s disease.

Breakdown of the intestinal mucosal barrier, and loss of the ability to self-repair if damaged, is a sign of Crohn’s disease and its complications.

The link between a dysregulated immune response and environmental and systemic factors such as the microbiome may be key to understanding the pathogenesis of Crohn’s disease.

News & Insights
}

Published Wed Dec 7, 2022

Highlights from the 2022 Gut Cell Atlas Convening

In September, the Helmsley Charitable Trust Crohn’s Disease Program hosted a two-day meeting focused ...
}

Published Fri Dec 2, 2022

Supporting Promising Therapeutics Through the Valley of Death

While Thetis Pharmaceuticals has a promising scientific platform which may someday improve lives for people ...
}

Published Tue May 31, 2022

A Preview of Helmsley at Aspen Ideas: Health

Crohn’s Disease Program Director Dr. Paul Scholl has a post in the Aspen Ideas ...

Understanding the Emergence of Crohn’s Disease in South Asians


Groundbreaking research study sheds light on environmental factors that may contribute to a growing incidence ...

Expanding Access to Telemedicine for People Living with Crohn’s Disease


A Conversation with Dr. Corey Siegel Last month, Helmsley announced a grant of $593,736 to Dartmouth-Hitchcock ...

Cell-Based Therapies for the Treatment of Crohn’s Disease

One aim of the Crohn’s Disease Therapeutics pillar is to identify top researchers whose findings...
Cell-Based Therapies for the Treatment of Crohn’s Disease

Sneha Dave of Health Advocacy Summit Quoted in CNN COVID Coverage

CNN quotes Sneha Dave, founder and executive director of Helmsley grantee Health Advocacy Summit, while...
Sneha Dave of Health Advocacy Summit Quoted in CNN COVID Coverage

Findings from the Diet & IBD Workshop

Co-hosted by Helmsley and the Kenneth Rainin Foundation, a workshop held in April 2018 brought...
Findings from the Diet & IBD Workshop

Helmsley Funds Dartmouth-Hitchcock to Expand Telehealth across Northern New England

Access to Holistic, Specialty Care for Crohn’s Disease to Increase
Helmsley Funds Dartmouth-Hitchcock to Expand Telehealth across Northern New England

Helmsley Funds the Asian Healthcare Foundation in Southern India to Improve Care for Crohn’s Disease Patients Living Below the Poverty Line

Crohn’s disease on the rise in India; new grant will help raise awareness and prevent...
Helmsley Funds the Asian Healthcare Foundation in Southern India  to Improve Care for Crohn’s Disease Patients Living Below the Poverty Line
Recent Grants

The Sheba Fund for Health Services and Research (R.A.)

Amount: $2,447,647
Term of Grant: 42 Months
Date of Award: 11.08.2022

Clalit Health Services

Amount: $1,360,291
Term of Grant: 36 Months
Date of Award: 11.08.2022

Clalit Health Services

Amount: $422,087
Term of Grant: 36 Months
Date of Award: 11.08.2022

Ben-Gurion University of the Negev

Amount: $2,770,874
Term of Grant: 36 Months
Date of Award: 11.08.2022

Shaare Zedek Medical Center

Amount: $3,066,299
Term of Grant: 36 Months
Date of Award: 11.08.2022

Array ( [1] => 3021 [2] => 3067 [3] => 3030 [11] => 3055 [13] => 56634 [17] => 3105 [19] => 62780 [21] => 3029 [25] => 3028 [27] => 3061 [29] => 62090 )
Our Team

Dr. Paul Scholl is the Program Director of the Helmsley Charitable Trust’s Crohn’s Disease Program.


Prior to joining Helmsley, he was associate medical head for the immunology the...
Read More

Paul Scholl

Program Director

Dr. Laurie Churchill is a Program Officer for the Helmsley Charitable Trust’s Crohn’s Disease Program. Laurie oversees the diagnostics portfolio of grants, identifying and evaluating new opport...
Read More

Laurie Churchill

Program Officer

Dr. Terry Felton is a Program Officer for the Helmsley Charitable Trust’s Crohn’s Disease Program. In this role, Terry oversees the disease management grants portfolio and helps identify and evalu...
Read More

Terry Felton

Program Officer

Dr. Jessica Langer is a Program Officer for the Helmsley Charitable Trust’s Crohn’s Disease Program. Jessica helps to manage the program’s research grants portfolio and to identify new opport...
Read More

Jessica Langer

Program Officer

Dr. Elena Lucchetta is a Program Officer for the Helmsley Charitable Trust’s Crohn’s Disease Program. In this role, Elena oversees a portfolio of grants focusing on the underlying biology of Crohn...
Read More

Elena Lucchetta

Program Officer

Dr. Shefali Soni is a Program Officer for the Crohn’s Disease Program. In this role, Shefali oversees and manages the prevention grants portfolio and helps identify and evaluate new initiatives w...
Read More

Shefali Soni

Program Officer

Ariela Bauer
Dr. Ariela Baur is an Associate Program Officer for Helmsley’s Crohn’s Disease Program. In this role, Ariela contributes to the therapeutics portfolio of grants to promote novel therapeutics and i...
Read More

Ariela Bauer

Associate Program Officer

Dr. Kerry Hernandez is an Associate Program Officer for the Helmsley Charitable Trust’s Crohn’s Disease Program. Kerry contributes to managing the Program’s portfolio of prevention grants, wh...
Read More

Kerry Hernandez

Associate Program Officer

Dr. Stephanie LeValley is an Associate Program Officer for Helmsley’s Crohn’s Disease Program. In this role, Stephanie supports the therapeutics portfolio of grants to promote novel therapeutic...
Read More

Stephanie LeValley

Associate Program Officer

Kortney Hensley is an Administrative Assistant for Helmsley’s Crohn’s Disease Program. As Administrative Assistant, she provides scheduling, travel, and expense reporting support for the progra...
Read More

Kortney Hensley

Administrative Assistant

Minele Youssef is an Administrative Assistant for Helmsley’s Crohn’s Disease Program. She provides scheduling, travel, and expense reporting support for the program.
Read More

Minele Youssef

Administrative Assistant